Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors & Lymphomas

This study has been terminated.

First Received: August 24, 2001 Last Updated: June 23, 2005 History of Changes

Sponsor:	Enzon Pharmaceuticals, Inc.
Information provided by:	Enzon Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:	NCT00023166

Purpose

Studies of PEG-paclitaxel have been terminated

Condition	Intervention	Phase
Neoplasm Lymphomas Neoplasm Metastasis	Drug: PEG-paclitaxel	Phase I

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Official Title:	Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors and Lymphomas

Resource links provided by NLM:

MedlinePlus related topics: Cancer Lymphoma

Drug Information available for: Paclitaxel

U.S. FDA Resources

Further study details as provided by Enzon Pharmaceuticals, Inc.:

Study Start Date:	May 2001
Estimated Study Completion Date:	May 2002

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

None - Study has been terminated.

Contacts and Locations

No Contacts or Locations Provided

More Information

No publications provided

Study ID Numbers:	PTX-5001
Study First Received:	August 24, 2001
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00023166 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by Enzon Pharmaceuticals, Inc.:

Phase I
Open label
Safety/efficacy
Lymphomas

Advanced primary and/or metastatic solid tumors
Neoplasms
Neoplasm metastasis

Additional relevant MeSH terms:

Neoplasms by Histologic Type
Immunoproliferative Disorders
Molecular Mechanisms of Pharmacological Action
Immune System Diseases
Antineoplastic Agents
Mitosis Modulators
Antimitotic Agents
Pharmacologic Actions
Lymphatic Diseases
Neoplasms

Neoplastic Processes
Pathologic Processes
Paclitaxel
Therapeutic Uses
Tubulin Modulators
Neoplasm Metastasis
Lymphoproliferative Disorders
Antineoplastic Agents, Phytogenic
Lymphoma

ClinicalTrials.gov processed this record on November 27, 2009